Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT00788112
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

  • vorinostat — DRUG
  • protein expression analysis — GENETIC
  • immunohistochemistry staining method — OTHER
  • laboratory biomarker analysis — OTHER
  • neoadjuvant therapy — PROCEDURE
  • therapeutic conventional surgery — PROCEDURE

Study Details

RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This clinical trial is studying how well vorinostat works in treating women with ductal carcinoma in situ of the breast.

Key Dates

Start date
Jul 31, 2009
Status verified
Aug 2017
Primary completion
Nov 3, 2011
Completion
Aug 11, 2015

Study Design

Enrollment
17 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Experimental: Vorinostat

Primary Outcome Measure

Reduction in Ki-67 compared to baseline Ki-67 [ Time Frame: 3 days prior to surgery ]

Locations (1)

FacilityCityStateZIPSite coordinators
UCSF Helen Diller Family Comprehensive Cancer CenterSan FranciscoCalifornia94115-

Find similar trials in San Francisco, CA

By condition
Breast cancer
By specialty
OncologyBreast oncologyWomen's health
By research site
UCSF Helen Diller Family Comprehensive Cancer Center· San Francisco, CA

Related Studies